The Amount of Activating EGFR Mutations in Circulating Cell-Free DNA Is a Marker to Monitor Osimertinib Response

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0238-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Detection of EGFR Mutations in Circulating Free DNA by PNA-mediated PCR Clamping

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2013English

P1.01-46 Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

KRAS Mutations in Blood Circulating Cell-Free DNA: A Pancreatic Cancer Case-Control

Oncotarget
Oncology
2016English

Circulating Cell-Free DNA

2019English

Detection of Mutations in Circulating Cell‐free DNA in Relation to Disease Stage in Colorectal Cancer

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Circulating Cell-Free DNA and Its Integrity as a Prognostic Marker for Breast Cancer

SpringerPlus
Multidisciplinary
2015English

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

Circulating Cell Free DNA as the Diagnostic Marker for Colorectal Cancer: A Systematic Review and Meta-Analysis

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy